11444 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04191 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

SIP22–005, Building Resilience Against 

Climate Effects (BRACE): Enhancing 

Practical Guidance to Support Climate 

and Health Adaptation Planning. 

Date: May 4, 2022. 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: Jaya 

Raman, Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107– 

B, Atlanta, Georgia 30341, Telephone: 

(770) 488–6511, email: JRaman@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04262 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)- 

RFA–CK-22–001, Investigation of 

Monkeypox and Other Zoonotic 

Diseases in the Democratic Republic of 

the Congo (DRC); RFA–CK–22–002, 

Technological Advancement of Global 

Rabies Surveillance and Control; and 

RFA–CK–22–004, Optimization and 

Standardization of Methods to Suppress 

Ixodes scapularis and Disrupt Enzootic 

Pathogen Transmission in Settings 

Posing an Elevated Risk to Humans. 

Date: April 28, 2022. 

Time: 10:00 a.m.–5:00 p.m. (EDT). 

Place: Teleconference, Centers for 

Disease Control and Prevention, Room 

1080, 8 Corporate Square Blvd., Atlanta, 

GA 30329. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, CDC, 1600 Clifton 

Road NE, Mailstop US8–1, Atlanta, 

Georgia 30329, (404) 718–8833, 

ganderson@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04261 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

PAR 20–297, NIOSH Centers of 

Excellence for Total Worker Health 

(TWH). 

Date: April 21, 2022. 

Time: 1:00 p.m.–4:00 p.m., EDT. 

Place: Video-Assisted Meeting. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Dan 

Hartley, Ed.D., Scientific Review 

Officer, Office of Extramural Programs, 

National Institute for Occupational 

Safety and Health, CDC, 1095 

Willowdale Road, Morgantown, West 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 11445 

Virginia 26505, Telephone: (304) 285– 

5812; Email: DHartley@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04260 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day-22–22CX; Docket No. CDC–2022– 

0031] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), in the 

Department of Health and Human 

Services (HHS), as part of its continuing 

effort to reduce public burden, invites 

the general public and other federal 

agencies to take this opportunity to 

comment on proposed and/or 

continuing information collections, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Preferences for 

Longer-Acting Preexposure Prophylaxis 

(LA-PrEP) Methods Among Persons in 

U.S. Populations at Highest Need: A 

Discrete Choice Experiment. The 

proposed project is designed to 

understand preferences for LA-PrEP 

products for HIV prevention among 

potential users and providers. 

DATES: CDC must receive written 

comments on or before May 2, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0031, by either of the following 

methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7118; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Preferences for Longer-Acting 

Preexposure Prophylaxis (LA-PrEP) 

Methods Among Persons in U.S. 

Populations at Highest Need: A Discrete 

Choice Experiment—New—National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention (NCHHSTP), Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

The 2022–2025 National HIV/AIDS 

Strategy includes a goal of increasing 

pre-exposure prophylaxis (PrEP) 

coverage to 50 percent among persons 

with indications, from a 2017 baseline 

of 13.2 percent. Despite successes in 

development and scale up of daily oral 

PrEP as a biomedical HIV prevention 

product, studies consistently show 

obstacles to its uptake and continuation. 

The Centers for Disease Control and 

Prevention (CDC) and its partners must 

engage in early planning for the 

implementation of longer-acting PrEP 

(LA-PrEP) agents to help achieve the 

U.S. Ending the HIV Epidemic (EHE) 

goal of reducing incident HIV infections 

by 90 percent by 2030. Understanding 

providers’ and priority populations’ 

preferences for different LA-PrEP 

agents, and perceived advantages and 

disadvantages of each product, will be 

critical to estimating future uptake and 

use of the various products that are 

recently or soon likely to become 

available for prescription. 

The goal of this study is to understand 

preferences for LA-PrEP products for 

HIV prevention among potential users 

and providers, including product 

characteristics and other service 

delivery factors that may facilitate or 

hinder future uptake of these products. 

In cooperation with partners, CDC will 

conduct a discrete choice experiment 

(DCE) among providers and potential 

users of LA-PrEP products to elicit their 

preferences for characteristics of LAPrEP and delivery programs to 

maximize uptake of LA-PrEP among 

people in need of HIV prevention 

methods. Results from this experiment 

will be used to identify factors key to 

adoption and implementation of each 

product and increase implementation 

efficiency by identifying strategies to 

support decision making and address 

potential challenges. 

The study design is a cross-sectional, 

online survey comprised of a DCE and 

additional questions to directly elicit 

participant preferences and gather data 

on socioeconomic, behavioral, and 

attitudinal factors. DCE methods are 

based on the principle that products or 


jspears on DSK121TN23PROD with NOTICES1